Aldeyra Therapeutics has resubmitted a new drug application for topical reproxalap for the treatment of signs and symptoms of dry eye disease, the company announced in a press release.
“If approved, reproxalap would have the potential to be the first dry eye disease therapy for chronic use with pivotal data demonstrating acute activity in reducing dry eye symptoms and ocular redness, two characteristics of dry eye disease of primary importance to patients,” Todd C. Brady, MD, PhD, Aldeyra’s president and CEO, said in the release.
According to the release, the resubmission